Inherited retinal diseases are now the most common cause of blindness in working age adults in England and Wales, and the second commonest in childhood. Currently, there is no cure or specific treatment.
We looked for new and emerging technologies that aim to slow or stop disease progression and/or reverse sight loss. We asked clinical experts and two patient focus groups (facilitated by the charity Fight for Sight) to comment on the potential for future impact of the technologies we identified on patients and the health service. The patient focus groups provided valuable insights into the technologies from a potential user’s perspective.
Ranibizumab as intravitreal injections is in clinical development for the treatment of diabetic retinopathy in both its proliferative and non-proliferative forms. Diabetic retinopathy, is a disease that affect the retinas and other parts of the inner eye. It is a chronic progressive condition of the retinal blood vessels due to prolonged raised blood glucose. When new blood vessels and scar tissue form on the retina causing bleeding within the eye and loss of vision, it is called proliferative diabetic retinopathy.